Combination of immunotherapy, chemotherapy and targeted drugs
triple therapy is expected to bring new hope to patients with gastric cancer
Science and Technology Daily, Beijing, December 15 (Reporter Zhang Mengran) A cancer research report published in the British journal Nature showed that the combination of immunotherapy with chemotherapy and targeted drugs is expected to improve the receptor known as human epidermal growth factor- 2Prognosis of patients with protein (HER2) positive gastric tumors.
The study is based on an interim analysis of a Phase III clinical trial, which has prompted the US Food and Drug Administration to approve the clinical use of the therapy.
About 20% of patients with advanced gastric adenocarcinoma or gastroesophageal junction adenocarcinoma will overexpress HER2.
For more than ten years, the standard first-line therapy has been a combination of HER2 antibody trastuzumab and chemotherapy.
As part of the "KEYNOTE-811 Phase III clinical trial", the research team of Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College in the United States evaluated the additional drug pembrolizumab can bring Which treatment benefits.
Pembrolizumab is an antibody that helps the immune system recognize and attack tumor cells.
The trial counted the efficacy data of 264 enrolled patients.
The team found that adding pembrolizumab to trastuzumab and chemotherapy can shrink tumors in some patients and induce a complete response (temporary complete remission), and the complete response rate can increase from 3.1% to 11.3% ; The proportion of patients with the best response has also increased significantly.
In view of the good results of the trial, the research team recommends that the same triple therapy be tested in early patients of the disease.
In the future, the trial will continue to monitor the impact of this combination therapy on patient survival.